
Petra Zieglmayer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/206912/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	IgE recognition of the house dust mite allergen Der p 37 is associated with asthma. Journal of Allergy and Clinical Immunology, 2022, 149, 1031-1043.	2.9	19
2	lgE-reactivity patterns in Asian and central European cockroach sensitized patients reveal differences in primary sensitizing allergen sources. , 2022, , .		1
3	Clinical performance of house-dust-mite-specific subcutaneous immunotherapy in aÂpostmarket noninterventional setting. Allergo Journal International, 2021, 30, 46-49.	2.0	2
4	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
5	Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey. Current Medical Research and Opinion, 2021, 37, 1259-1272.	1.9	3
6	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3589-3612.	5.7	23
7	Expression in <i>Escherichia coli</i> and Purification of Folded rDer p 20, the Arginine Kinase From <i>Dermatophagoides pteronyssinus</i> : A Possible Biomarker for Allergic Asthma. Allergy, Asthma and Immunology Research, 2021, 13, 154.	2.9	14
8	Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy. Clinical and Translational Allergy, 2020, 10, 33.	3.2	12
9	Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32. EBioMedicine, 2020, 59, 102953.	6.1	10
10	Fast effectiveness of a solubilized lowâ€dose budesonide nasal spray in allergic rhinitis. Clinical and Experimental Allergy, 2020, 50, 1065-1077.	2.9	5
11	A novel water-soluble budesonide nasal spray (Budesolv 10) improves asthmatic symptoms promptly in patients suffering from grass pollen allergic symptoms induced in an allergen exposure chamber. Journal of Allergy and Clinical Immunology, 2020, 145, AB235.	2.9	0
12	The Role of Der p 23 Sensitization: An Analysis of 474 Patients Sensitized to Mite. International Archives of Allergy and Immunology, 2020, 181, 689-698.	2.1	6
13	Cetirizine inhibits gender-specific blood cell dynamics upon allergen contact in allergic rhinitis. Clinical Immunology, 2020, 215, 108422.	3.2	4
14	Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms. Journal of Allergy and Clinical Immunology, 2019, 143, 1258-1261.	2.9	29
15	Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season. World Allergy Organization Journal, 2019, 12, 100012.	3.5	3
16	P401 RAPID ONSET OF ACTION OF A NOVEL BUDESONIDE NASAL SPRAY IN GRASS POLLEN ALLERGIC RHINITIS. Annals of Allergy, Asthma and Immunology, 2019, 123, S57.	1.0	0
17	P451 SUPER- AND NON/LOW-RESPONDERS AMONG SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVITIS RECEIVING HOUSE DUST MITE SUBLINGUAL IMMUNOTHERAPY TABLET. Annals of Allergy, Asthma and Immunology, 2019, 123, S58.	1.0	0
18	Perspectives in allergen immunotherapy: 2019 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 3-25.	5.7	113

PETRA ZIEGLMAYER

#	Article	IF	CITATIONS
19	Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy. Journal of Allergy and Clinical Immunology, 2019, 143, 1248-1252.e12.	2.9	56
20	Clinical reactivity of celery cultivars in allergic patients: Role of Api g 1. Clinical and Experimental Allergy, 2018, 48, 424-432.	2.9	8
21	Perspectives in allergen immunotherapy: 2017 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 5-23.	5.7	76
22	Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1003-1012.	5.7	19
23	Underestimation of house dust mite–specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs. Journal of Allergy and Clinical Immunology, 2018, 142, 1656-1659.e9.	2.9	36
24	Clinical efficacy of sublingual immunotherapy is associated with restoration of steady-state serum lipocalin 2 after SLIT: a pilot study. World Allergy Organization Journal, 2018, 11, 21.	3.5	23
25	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an <scp>EAACI</scp> Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1035-1042.	5.7	85
26	Clinical validation of a house dust mite environmental challenge chamber model. Journal of Allergy and Clinical Immunology, 2017, 140, 266-268.e5.	2.9	13
27	Possible effect of landscape design on IgE recognition profiles of two generations revealed with microâ€arrayed allergens. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1579-1582.	5.7	9
28	Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis. Scientific Reports, 2017, 7, 2555.	3.3	6
29	Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. PLoS ONE, 2016, 11, e0160641.	2.5	30
30	Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. Annals of Allergy, Asthma and Immunology, 2016, 117, 690-696.e1.	1.0	25
31	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. EBioMedicine, 2016, 11, 58-67.	6.1	45
32	Epitope specificity determines crossâ€protection of a <scp>SIT</scp> â€induced IgG ₄ antibody. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 36-46.	5.7	16
33	Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine, 2016, 11, 43-57.	6.1	109
34	Structural and Functional Characterization of the Major Allergen Amb a 11 from Short Ragweed Pollen. Journal of Biological Chemistry, 2016, 291, 13076-13087.	3.4	23
35	Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 137, 1733-1741.	2.9	29
36	The improved efficacy of a fixedâ€dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clinical and Experimental Allergy, 2015, 45, 1346-1355.	2.9	17

PETRA ZIEGLMAYER

#	Article	IF	CITATIONS
37	Effects of Nasal Corticosteroids on Boosts of Systemic Allergen-Specific IgE Production Induced by Nasal Allergen Exposure. PLoS ONE, 2015, 10, e0114991.	2.5	12
38	Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. Journal of Allergy and Clinical Immunology, 2015, 135, 1494-1501.e6.	2.9	140
39	The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 576-584.	0.6	34
40	The <scp>CRTH</scp> 2 antagonist <scp>OC</scp> 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placeboâ€controlled, doubleâ€blind trial. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1572-1579.	5.7	77
41	Intranasal Toll-like Receptor 8 Agonist (VTX-1463) Significantly Improves Symptoms of Allergic Rhinitis in a Randomized, Placebo-Controlled Trial. Journal of Allergy and Clinical Immunology, 2011, 127, AB199-AB199.	2.9	7
42	Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1530-1537.	5.7	50
43	The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation Research, 2010, 59, 391-398.	4.0	69
44	Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. Journal of Allergy and Clinical Immunology, 2009, 124, 471-477.e1.	2.9	174
45	A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Annals of Allergy, Asthma and Immunology, 2009, 102, 116-120.	1.0	48
46	Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Current Medical Research and Opinion, 2008, 24, 1833-1840.	1.9	31